Straits Times Index
3,415.51 +47.61 (+1.41%) S&P 500
5,515.60 +6.59 (+0.12%) Dow
39,367.87 +36.02 (+0.09%) Nasdaq
18,046.86 +18.10 (+0.10%) Bitcoin USD
60,430.07 -2,420.18 (-3.85%) CMC Crypto 200
1,297.32 -37.60 (-2.82%)
AMRX Jul 2024 7.500 call
| Previous close | 0.1500 |
| Open | 0.1000 |
| Bid | 0.0500 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.12k |
- Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
PISCATAWAY, N.J., July 01, 2024--Kashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States.
Business WireAmneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
BRIDGEWATER, N.J., July 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the addition of omalizumab, referencing XOLAIR®, to its biosimilar pipeline.
Business WireAmneal Releases 2023 Environmental, Social and Governance Report
BRIDGEWATER, N.J., June 28, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-profit
